Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2025)

Historic Research & Development for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $809777.0.

  • 60 Degrees Pharmaceuticals' Research & Development fell 1385.93% to $809777.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 5346.87%. This contributed to the annual value of $5.0 million for FY2024, which is 62083.58% up from last year.
  • 60 Degrees Pharmaceuticals' Research & Development amounted to $809777.0 in Q3 2025, which was down 1385.93% from $249884.0 recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Research & Development peaked at $3.1 million during Q2 2024, and registered a low of $27655.0 during Q3 2022.
  • Its 4-year average for Research & Development is $543434.6, with a median of $256793.5 in 2023.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Research & Development skyrocketed by 141826.93% in 2024, and later plummeted by 9192.71% in 2025.
  • 60 Degrees Pharmaceuticals' Research & Development (Quarter) stood at $203457.0 in 2022, then crashed by 50.75% to $100201.0 in 2023, then skyrocketed by 512.72% to $613955.0 in 2024, then soared by 31.9% to $809777.0 in 2025.
  • Its Research & Development was $809777.0 in Q3 2025, compared to $249884.0 in Q2 2025 and $407622.0 in Q1 2025.